Overview of Protein Kinase B Enzyme: A Potential Target for Breast and Prostate Cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The PI3K/AKT/mTOR pathway regulates critical cellular processes including survival, proliferation, metabolism, and apoptosis.
• The AKT family comprises three isoforms (AKT1, AKT2, AKT3) with conserved kinase domains and substrate specificities.
• AKT signaling is implicated in various cancers, notably breast and prostate cancers, despite its absence in some tumors.

Purpose of the Study:

• To review current insights into AKT inhibitors for drug development.
• To discuss the protein structure and mechanisms of AKT inhibitors.
• To highlight the role of AKT in breast and prostate cancer development and its potential as a drug target.

Main Methods:

• Literature review of AKT inhibitors and their mechanisms.
• Analysis of AKT protein structure and isoform homology.
• Examination of AKT's role in breast and prostate carcinogenesis.

Main Results:

• Limited AKT inhibitors exist, with a lack of isoform selectivity.
• AKT signaling is crucial for carcinogenesis in major global cancers.
• Understanding AKT structure and function is key for targeted drug development.

Conclusions:

• Targeting AKT signaling presents a promising therapeutic strategy for breast and prostate cancers.
• Further development of selective AKT inhibitors is needed.
• Continued research into AKT's role in cancer is essential for advancing treatment options.